Sign in Membership
Commercial Health Insurance & C-List Dynamics

▶️Making the C-List Work: Lessons and Next Steps for Pharma

The final Health Policy and Financing Panel wrapped up the C-List Masterclass with reflections, insurer perspectives, global case studies, and Q&A—highlighting how manufacturers can turn C-List inclusion into a true springboard for coverage.

In the closing Health Policy and Financing Panel of the C-List Masterclass, we brought together insights from earlier sessions and looked ahead to what the C-List means for pharma strategies in China.

The discussion explored several critical themes:

  • Reflections on prior sessions and how they connect to the evolving C-List landscape.
  • Commercial insurers’ perspectives—why their priorities matter for shaping go-to-market strategies and commercial negotiations.
  • Practical next steps for manufacturers to make C-List inclusion a genuine springboard for coverage, not just a symbolic listing.
  • Two global case studies offering concrete lessons from outside China that pharma can adapt to shape and strengthen their C-List pathway engagement.
  • Q&A, where participants raised questions on C-List inclusion priorities, pull-through strategies, and how upcoming reforms may affect multinational vs. local players.

This panel tied the series together with both reflection and forward-looking insights, giving manufacturers pragmatic guidance on how to engage more proactively in China’s emerging multi-level coverage era.

Panelists:

Sejal Mistry

  • Senior Director, Crowell Global Advisors; advises on UHC, health financing, and service innovation in Asia-Pacific
  • Led Indonesia’s cervical cancer elimination plan
  • Former ACCESS Health SEA head

Neil Grubert

  • Former VP, Global Market Access Insights, DRG; now independent consultant
  • Advised 14 of the top 20 pharma companies worldwide
  • Influential LinkedIn voice (25K+ followers); founded Future of Market Access LinkedIn community

Kelly Ke

  • Award-winning former Senior Advisor, Deloitte US Life Sciences Practice
  • Founder, bizi LLC, an access intelligence consultancy
  • Architect of NRDL+ Executive Debrief, interpreting regulatory signals and implementation dynamics shaping medicine access across China’s multi-layer coverage system

You might also like...

Feb 12, 2026

Three Shifts Reshaping China’s Drug Payment System: Implications for Global Pharma

China’s drug payment system is shifting from isolated policy levers toward an environment defined by their interaction. Recent signals are beginning to link pricing, launch timing, and multi-payer access in ways that materially change how global pharma approaches China.
Jan 14, 2026

From Reference Tool to Operating Model: A Roadmap for China’s C-List

China’s C-List establishes a national reference for innovative drugs outside the NRDL—but not yet a payment system. Its impact will hinge on whether insurers and regulators can turn policy intent into a workable, risk-sustainable commercial coverage model.
Nov 05, 2025

NFRA’s Guiding Opinions: What They Mean for China’s Multi-Level Coverage Framework

NFRA’s latest Guiding Opinions signal a shift toward a more innovation-friendly commercial health insurance ecosystem. The article unpacks five key policy themes with critical implications for the C-List rollout and the building of China’s multi-level coverage framework.
Oct 01, 2025

Winning in China in a Multi-Level Coverage Era for Global Pharma

Success in China’s multi-level coverage era will hinge on three imperatives that upend old models and open new pathways.
Aug 13, 2025

▶️Frontline Perspectives: Realities and the Road Ahead for Commercial Health Insurance in China

Two senior commercial insurance leaders share candid views on China’s evolving market—what’s working, where integration lags, and if the new commercial innovative drug list could help close gaps and drive future growth.